Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer
This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab in combined with chemoradiotherapy for unresectable,local advanced squamous cell lung cancer.
Non-small-cell Lung Cancer
DRUG: Nimotuzumab|DRUG: docetaxel and cisplatin|RADIATION: daily RT to the chest
overall survival, 3 years
Objective Response Rate, 3 years|progression-free survival, 3 years|rate of grade 3-4 radiation esophagitis, rate of grade 3-4 radiation esophagitis as assessed by CTCAE v4.0, 1 years|rate of grade 3-4 radiation pneumonitis, rate of grade 3-4 radiation pneumonitis as assessed by CTCAE v4.0, 1 year|Failure patterns, rates of local-regional recurrence, distant metastasis and brain metastasis, 3 years
This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab combined with chemoradiotherapy for unresectable,locally advanced squamous cell lung cancer.

All patients were planned to receive radical dose of chest radiation and concurrent chemotherapy of weekly docetaxel and cisplatin, each of 1 day's duration.

Nimotuzumab group was treated with weekly nimotuzumab (200mg, IV) combined with chemoradiotherapy, while control group was treated with chemoradiotherapy.